Fonar Corporation has released its financial results for the fiscal year ending June 30, 2025. Total revenues increased by 1% to $104.4 million, compared to $102.9 million for the previous fiscal year. Revenue from the management of the diagnostic imaging center segment, which includes patient fee revenue and management fees, rose 1% to $95.4 million. Revenues from product sales and upgrades, as well as service and repair fees, increased to $9.0 million from $8.3 million in the prior year. Net income for the fiscal year decreased by 24% to $10.7 million from $14.1 million in the previous year. Income from operations fell 30% to $11.6 million, down from $16.5 million in the prior fiscal year. Diluted net income per common share decreased by 20% to $1.23. Operating cash flow was reported at $11.3 million, a decrease from the previous year's $14.1 million. Working capital experienced a 4% increase, reaching $127.5 million. Meanwhile, the book value per share increased to $25.26. In terms of expenses, total costs and expenses grew by 7% to $92.8 million, and selling, general and administrative expenses rose by 11% to $29.7 million. On the other hand, research and development expenses decreased by 9% to $1.6 million. Chairman and CEO Timothy Damadian noted that their diagnostic imaging management subsidiary, Health Management Company of America (HMCA), has continued to grow, with scan volumes at HMCA-managed sites increasing each fiscal year since 2020, achieving a record of 216,317 scans in fiscal 2025.